Shares shifted sharply higher as Teradyne jumped 8.2% to $380.41 on July 9, extending a rally fueled by the company's grip on AI chip testing, accelerating robotics revenue, and fresh index-fund buying after its June addition to the Nasdaq-100. The move caps a volatile stretch — the stock touched $427 just eight days ago before pulling back — and forces investors to weigh explosive growth against a valuation some analysts call stretched.
Nearly 70% of Revenue Now Comes From AI, and That Concentration Cuts Both Ways
AI-related demand represented nearly 70% of Q1 2026 revenue, up from about 60% in Q4 2025.
Q1 revenue hit a record $1.282 billion, up 87% year-over-year , crushing the $1.22 billion Street consensus. The semiconductor test segment alone generated $1.1 billion, breaking the $1 billion threshold for the first time. That's extraordinary growth, but it also concentrates the business into a smaller set of vertically integrated customers and fewer large device programs — meaning any pause in data-center spending could hit hard.
Robotics Is Finally Pulling Its Weight
The robotics division delivered its fourth consecutive quarter of sequential growth, with Q1 revenues up 32% year-over-year to $91 million.
AI now represents 15% of robotics sales , and Teradyne expects its large e-commerce customer to triple its revenue contribution in 2026 compared with 2025. After years of post-pandemic stagnation — robotics revenue peaked at $326 million in 2022, then declined to $293 million in 2024 — this rebound gives the bull case a second engine beyond chip testing.
Nasdaq-100 Entry Brings Automatic Buyers, Not Automatic Value
Teradyne was added to the Nasdaq-100 effective June 22, 2026 , meaning every passive fund tracking the index had to buy shares. That institutional buying has pushed the forward price-to-earnings ratio to an elevated 56x–64x range.
Analysts caution the stock is overvalued relative to its fundamental fair value, leaving it vulnerable to profit-taking now that passive demand flows have subsided.
The Numbers Ahead Will Decide Everything
Management guided Q2 revenue to $1.15–$1.25 billion and reiterated a full-year target of $6 billion in revenue and $9.50–$11.00 in non-GAAP earnings per share.
BofA raised its price target to $525; Baird set $446 — a wide spread that reflects genuine uncertainty. With gross margins around 58–59% and nearly zero debt, the balance sheet is clean. The question is whether AI-driven testing demand stays hot enough to justify paying more than 60 times earnings for what is, at its core, a cyclical equipment maker.